Level Biotechnology Inc.(TW:3118)
NT$30.15-0.45 (-1.47%)
TW:3118
Level Biotechnology Inc. financials statements
NT$30.15
At close:-0.45 (-1.47%)
Level Biotechnology Inc. (3118) Ratios
Level Biotechnology Inc. Ratios
TW:3118's free cash flow for Q2 2026 was NT$35.42M. For the 2026 fiscal year, TW:3118's free cash flow was decreased by NT$-317.00K and operating cash flow was NT$35.74M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.82 | 1.92 | 2.69 | 2.62 | 2.82 |
| Quick Ratio | 1.40 | 1.53 | 2.34 | 2.33 | 2.57 |
| Cash Ratio | 0.77 | 1.00 | 1.85 | 1.82 | 2.10 |
| Solvency Ratio | 0.36 | 0.32 | 0.30 | 0.29 | 0.36 |
| Operating Cash Flow Ratio | 0.22 | 0.25 | 0.28 | 0.26 | 0.69 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 788.88 | 409.26 | 847.55 |
| Net Current Asset Value | NT$ 213.32M | NT$ 216.75M | NT$ 407.30M | NT$ 395.69M | NT$ 391.46M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
| Debt-to-Capital Ratio | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.49 | 1.48 | 1.50 | 1.50 | 1.45 |
| Debt Service Coverage Ratio | 440.62 | 308.24 | 197.05 | 154.47 | 157.21 |
| Interest Coverage Ratio | 417.73 | 268.77 | 203.47 | 186.51 | 208.90 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.25 | 0.40 | 0.43 | 0.40 | 0.42 |
| Net Debt to EBITDA | -1.91 | -2.34 | -4.60 | -4.85 | -4.37 |
| Profitability Margins | |||||
| Gross Profit Margin | 33.17% | 32.42% | 33.23% | 34.16% | 34.33% |
| EBIT Margin | 11.34% | 11.13% | 11.96% | 12.40% | 12.59% |
| EBITDA Margin | 14.39% | 14.03% | 14.94% | 15.68% | 15.51% |
| Operating Profit Margin | 11.34% | 10.29% | 10.23% | 10.94% | 11.66% |
| Pretax Profit Margin | 13.25% | 11.09% | 11.91% | 12.34% | 12.53% |
| Net Profit Margin | 10.82% | 8.86% | 9.52% | 9.86% | 10.07% |
| Continuous Operations Profit Margin | 10.82% | 8.86% | 9.52% | 9.86% | 10.07% |
| Net Income Per EBT | 81.68% | 79.89% | 79.98% | 79.92% | 80.31% |
| EBT Per EBIT | 116.79% | 107.80% | 116.43% | 112.72% | 107.51% |
| Return on Assets (ROA) | 9.19% | 7.84% | 7.65% | 7.20% | 8.66% |
| Return on Equity (ROE) | 13.74% | 11.58% | 11.45% | 10.78% | 12.51% |
| Return on Capital Employed (ROCE) | 14.11% | 13.10% | 11.85% | 11.63% | 14.04% |
| Return on Invested Capital (ROIC) | 11.44% | 10.38% | 9.42% | 9.25% | 11.23% |
| Return on Tangible Assets | 9.19% | 7.84% | 7.65% | 7.20% | 8.66% |
| Earnings Yield | 7.44% | 6.24% | 6.36% | 6.52% | 7.01% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.53 | 6.31 | 5.86 | 4.91 | 6.87 |
| Payables Turnover | 7.27 | 9.34 | 8.75 | 5.99 | 9.30 |
| Inventory Turnover | 4.26 | 5.04 | 4.96 | 5.30 | 7.92 |
| Fixed Asset Turnover | 2.28 | 2.34 | 6.24 | 5.25 | 5.53 |
| Asset Turnover | 0.85 | 0.88 | 0.80 | 0.73 | 0.86 |
| Working Capital Turnover Ratio | 3.23 | 2.22 | 1.57 | 1.45 | 1.71 |
| Cash Conversion Cycle | 116.04 | 91.24 | 94.17 | 82.23 | 59.94 |
| Days of Sales Outstanding | 80.52 | 57.89 | 62.33 | 74.27 | 53.09 |
| Days of Inventory Outstanding | 85.71 | 72.44 | 73.53 | 68.90 | 46.09 |
| Days of Payables Outstanding | 50.20 | 39.09 | 41.69 | 60.93 | 39.25 |
| Operating Cycle | 166.24 | 130.33 | 135.86 | 143.16 | 99.19 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.84 | 1.98 | 2.17 | 2.01 | 4.81 |
| Free Cash Flow Per Share | 0.83 | -4.92 | 1.93 | 1.80 | 4.52 |
| Dividend Paid and CapEx Coverage Ratio | 0.65 | 0.23 | 1.12 | 0.95 | 2.55 |
| Capital Expenditure Coverage Ratio | 1.82 | 0.29 | 9.16 | 9.66 | 17.03 |
| Operating Cash Flow Coverage Ratio | 7.47 | 5.05 | 5.20 | 5.11 | 11.67 |
| Operating Cash Flow to Sales Ratio | 0.08 | 0.09 | 0.11 | 0.11 | 0.23 |
| Free Cash Flow Yield | 2.52% | -15.37% | 6.32% | 6.50% | 15.10% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 13.41 | 16.08 | 15.72 | 15.36 | 14.26 |
| Price-to-Sales (P/S) Ratio | 1.45 | 1.42 | 1.50 | 1.51 | 1.44 |
| Price-to-Book (P/B) Ratio | 1.85 | 1.85 | 1.80 | 1.65 | 1.78 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 39.75 | -6.51 | 15.81 | 15.38 | 6.62 |
| Price-to-Operating Cash Flow Ratio | 17.97 | 16.20 | 14.09 | 13.79 | 6.23 |
| Price-to-Earnings Growth (PEG) Ratio | 0.57 | 6.24 | 2.02 | -1.08 | 0.82 |
| Enterprise Value Multiple | 8.19 | 7.78 | 5.42 | 4.80 | 4.88 |
| Enterprise Value | 868.59M | 798.40M | 535.07M | 446.56M | 512.37M |
| EV to EBITDA | 8.19 | 7.78 | 5.42 | 4.80 | 4.88 |
| EV to Sales | 1.18 | 1.09 | 0.81 | 0.75 | 0.76 |
| EV to Free Cash Flow | 32.24 | -5.00 | 8.56 | 7.66 | 3.49 |
| EV to Operating Cash Flow | 14.57 | 12.46 | 7.62 | 6.86 | 3.29 |
| Tangible Book Value Per Share | 17.88 | 17.25 | 16.95 | 16.71 | 16.79 |
| Shareholders’ Equity Per Share | 17.88 | 17.25 | 16.95 | 16.71 | 16.79 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | 0.20 | 0.20 | 0.20 | 0.20 |
| Revenue Per Share | 22.70 | 22.54 | 20.37 | 18.27 | 20.87 |
| Net Income Per Share | 2.46 | 2.00 | 1.94 | 1.80 | 2.10 |
| Tax Burden | 0.82 | 0.80 | 0.80 | 0.80 | 0.80 |
| Interest Burden | 1.17 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| SG&A to Revenue | 0.20 | 0.20 | 0.21 | 0.21 | 0.20 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.61 | 0.79 | 1.12 | 1.11 | 2.29 |
Currency in TWD
